Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer (original) (raw)
References
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15–year survival: an overview of the randomised trials. Lancet 365:1687–1717 ArticleCAS Google Scholar
Johnston S (2005) Molecular insights into endocrine resistance. Eur J Cancer Suppl 3:225–236 ArticleCAS Google Scholar
Osborne K, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res Suppl 11:865–870 Google Scholar
Arpino G, Weiss H, Lee A, Schiff R, De Placido S, Osborne K, Elledge R (2005) Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261 ArticlePubMedCAS Google Scholar
Kurebayashi J (2005) Resistence to endocrine therapy in breast cancer. Cancer Chemother Pharmacol Suppl 1 56:39–46 ArticleCAS Google Scholar
Arpino G, Green S, Allred C, Lew D, Martino S, Osborne K, Elledge R (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 10:5670–5676 ArticlePubMedCAS Google Scholar
Ellis M, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller W, Evans D, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1– and/or erbB-2–positive, estrogen receptor–positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816 PubMedCAS Google Scholar
Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C (2001) Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376–3384 PubMedCAS Google Scholar
Dowsett M, Houghton J, Iden C, Salter J, Farndon J, Hern RA, Sainsbury R, Baum M (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818–826 ArticlePubMedCAS Google Scholar
Osborne K, Bardou V, Hopp T, Chamness G, Hilsenbeck S, Fuqua S, Wong J, Allred C, Clark G, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361 ArticlePubMedCAS Google Scholar
Kirkegaard T, McGlynn L, Campbell F, Müller S, Tovey S, Dunne B, Nielsen K, Cooke T, Bartlett J (2007) Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13:1405–1411 ArticleCAS Google Scholar
Iwase H, Omoto Y, Toyama T, Yamashita H, Hara Y, Sugiura H, Zhang Z (2003) Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat 80:339–345 ArticlePubMedCAS Google Scholar
Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543–1549 Article Google Scholar
Rydén L, Jönsson P-E, Chebil G, Dufmats M, Fernö M, Jirström K, Källström A-C, Landberg G, Stål O, Thorstenson S, Nordenskjöld B (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41:256–264 ArticlePubMedCAS Google Scholar
Chebil G, Bendahl PO, Idvall I, Ferno M (2003) Comparison of immunohistochemical and biological assay of steroid receptors in primary breast cancer–clinical associations and reasons for discrepancies. Acta Oncol 42:719–725 ArticlePubMedCAS Google Scholar
Sigurdsson H, Baldetorp B, Borg Å, Dalberg M, Fernö M, Killander D, Olsson H (1990) Indicators of prognosis in node-negative breast caner. N Engl J Med 322:1045–1053 ArticlePubMedCAS Google Scholar
Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM (2004) Interlaboratory comparison of HER-2 oncogene aplification as detected by chromogenic and fluoroscence in situ hybridization. Clin Cancer Res 10:4793–4798 ArticlePubMedCAS Google Scholar
Sarvilinna N, Eronen H, Miettinen S, Vienonen A, Ylikomi T (2006) Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. Int J Cancer 118:832–840 ArticlePubMedCAS Google Scholar
Yarden RI, Wilson MA, Chrysogelos SA (2001) Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J Cell Biochem 81(Suppl. 36):232–246 Article Google Scholar
Schiff R, Massarweh SA, Shou J, Bharwani L, Moshin S, Osborne K (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10(Suppl):331–336 Article Google Scholar
De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco A (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039–1046 PubMed Google Scholar
Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT (2006) Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: A comparison between whole sections and tissue microarrays J Clin Pathol 60:397–404 ArticlePubMed Google Scholar
Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M, Milano G (2001) Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12:841–846 ArticlePubMedCAS Google Scholar
DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, More II D, Thor AD (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23:1152–1160 ArticlePubMedCAS Google Scholar
Niu Y, Fu X, Lv A, Fan Y, Wang Y (2002) Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer 98:754–760 ArticlePubMedCAS Google Scholar
Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S (2002) Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71:67–75 ArticlePubMed Google Scholar